Given the already established role of immune checkpoint blockade as standard therapy in advanced melanoma cases, there is the potential for combination therapy that pairs anti-PD-1 and anti-CTLA-4 antibodies with ACT to produce better clinical outcomes; some studies with lymphoma and malignant plural disease patients have already begun to move in this direction [131,132]. Here, CTLA4 is linked to melanoma.